Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
复制标题
DOI：
10.1182/blood-2004-04-1319
复制
发表时间：
2004-11-01
期刊：
影响因子：
20.3
通讯作者：
San Miguel, JF
中科院分区：
文献类型：
--
作者：
Gutiérrez, NC;García, JL;San Miguel, JF
通过核型或荧光原位杂交 (FISH) 评估的细胞遗传学异常被认为是多发性骨髓瘤 (MM) 最重要的预后因素。然而，没有关于通过比较基因组杂交（CGH）检测到的基因组变化对预后影响的信息。我们分析了 74 名新诊断的 MM 患者中 CGH 检测到的遗传变化的频率和预后影响，并通过 FISH 分析评估了这些染色体失衡与 IGH 易位之间的关系。 74 名 MM 患者中有 51 名 (69%) 发现了基因组变化。在基因组改变的病例中，最常见的异常是染色体区域1q（45%）、5q（24%）、9q（24%）、11q（22%）、15q（22%）、3q（16%）和7q（14%）区域的增加，而损失主要涉及染色体13（39%）、16q（18%）、6q（10%）和8便士（10%）。值得注意的是，. 6 名 11q 增益的患者患有 IGH 易位。多变量分析选择染色体丢失、11q 增益、年龄和治疗类型（传统化疗与自体移植）作为预测生存的独立参数。无论治疗方法如何，基因组损失仍保留预后价值。根据这些结果，CGH 评估的染色体材料丢失代表了 MM 患者的一个强大的预后因素。 (C) 2004 年，美国血液学会。
Cytogenetic abnormalities, evaluated either by karyotype or by fluorescence in situ hybridization (FISH), are considered the most important prognostic factor in multiple myeloma (MM). However, there is no information about the prognostic impact of genomic changes detected by comparative genomic hybridization (CGH). We have analyzed the frequency and prognostic impact of genetic changes as detected by CGH and evaluated the relationship between these chromosomal imbalances and IGH translocation, analyzed by FISH, in 74 patients with newly diagnosed MM. Genomic changes were identified in 51 (69%) of the 74 MM patients. The most recurrent abnormalities among the cases with genomic changes were gains on chromosome regions 1q (45%), 5q (24%), 9q (24%), 11q (22%), 15q (22%), 3q (16%), and 7q (14%), while losses mainly involved chromosomes 13 (39%), 16q (18%), 6q (10%), and 8p (10%). Remarkably, the. 6 patients with gains on 11q had IGH translocations. Multivariate analysis selected chromosomal losses, 11q gains, age, and type of treatment (conventional chemotherapy vs autologous transplantation) as independent parameters for predicting survival. Genomic losses retained the prognostic value irrespective of treatment approach. According to these results, losses of chromosomal material evaluated by CGH represent a powerful prognostic factor in MM patients. (C) 2004 by The American Society of Hematology.